notice received, page-37

ASX & Media Release

PAT-LM1 Advancing to the Clinic

? Lymphoma – likely blood cancer indication for PAT-LM1
? PAT-LM1 enters scale-up manufacturing

Melbourne, Australia; 24 March, 2014: Patrys Limited (ASX: PAB), a clinical stage biotechnology
company, is pleased to provide an update on the development programme for anti-cancer product,
PAT-LM1.
PAT-LM1 is the second IgM antibody in Patrys’ pipeline to enter clinical development. PAT-LM1 is a
natural human antibody that has shown great promise in preclinical development as a potential
treatment for multiple types of cancer, including colon, lung, breast, ovary, pancreatic and various
haematological cancers.
The most recent laboratory experiments focused on the evaluation of the efficacy of PAT-LM1 in
blood cancers including different types of leukaemias and lymphomas. PAT-LM1 showed very strong
and specific binding to more than 90% of tested lymphoma cell lines and patients samples. PAT-LM1
was able to induce cell death in mantle cell lymphoma and histiocytic lymphoma cells. Interestingly,
PAT-LM1 also bound specifically and strongly to some very rare lymphoma types like marginal zone
B-cell and Burkitt lymphoma, indicating that it may have broad therapeutic application covering the
whole range of different lymphomas. Despite there being numerous drugs on the market for
lymphoma, there is still a significant unmet medical need especially in patients with relapsed and
refractory disease. The prognosis for these patients is poor and therefore the development of novel
agents, such as PAT-LM1, is urgently needed.

The cell line development of PAT-LM1 for production has been successfully completed and early data
indicate that the resultant yield from a GMP manufacturing run is likely to be significantly higher than
yields achieved to date. Patrys has now commenced the manufacturing process to produce PAT-LM1
for a future clinical trial.

Patrys’ CEO, Dr. Marie Roskrow, said: “The results demonstrated in this preclinical work confirm the
potential of PAT-LM1 as an effective therapy for a broad range of lymphomas. Currently we
anticipate that this antibody will be moved into clinical trial at the University of Würzburg where we
will be working with the same clinicians who successfully executed the recent PAT-SM6 multiple
myeloma trial. Professor Einsele and his team are very excited by the prospects for PAT-LM1 in
treating patients with relapsed and refractory lymphomas.”